Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study.
Algorithms
Biomarkers
Disease Management
Early Detection of Cancer
Female
Humans
Image Processing, Computer-Assisted
Kaplan-Meier Estimate
Magnetic Resonance Imaging
Male
Neuroendocrine Tumors
/ diagnostic imaging
Prognosis
Radiography
/ methods
Reproducibility of Results
Retrospective Studies
Tomography, X-Ray Computed
Treatment Outcome
Tumor Burden
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 11 2019
15 11 2019
Historique:
received:
21
03
2019
revised:
23
05
2019
accepted:
30
07
2019
pubmed:
4
8
2019
medline:
12
9
2020
entrez:
4
8
2019
Statut:
ppublish
Résumé
Tumor growth rate (TGR) represents the percentage change in tumor volume per month (%/m). Previous results from the GREPONET study showed that TGR measured after 3 months (TGR Patients from 7 centers with advanced grade (G) 1/2 NETs from the pancreas (P)/small bowel (SB) initiating ST/WW were eligible. Computed tomography (CT)/MRI performed at prebaseline, baseline, and 3(±1) months of study entry were retrospectively reviewed. Aim-1: explore treatment-induced changes in TGR (ΔTGR Of 785 patients screened, 127 were eligible. Mean (SD) TGR TGR has a role as a biomarker for monitoring response to therapy for early identification of treatment-induced changes and for early prediction of PFS and radiologic objective response.
Identifiants
pubmed: 31375514
pii: 1078-0432.CCR-19-0963
doi: 10.1158/1078-0432.CCR-19-0963
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6692-6699Informations de copyright
©2019 American Association for Cancer Research.